HomeCompareGSFD vs PFE

GSFD vs PFE: Dividend Comparison 2026

GSFD yields 2760.91% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GSFD wins by $206334347642.39M in total portfolio value
10 years
GSFD
GSFD
● Live price
2760.91%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$206334347642.44M
Annual income
$192,610,786,326,095,000.00
Full GSFD calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GSFD vs PFE

📍 GSFD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGSFDPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GSFD + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GSFD pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GSFD
Annual income on $10K today (after 15% tax)
$234,676.97/yr
After 10yr DRIP, annual income (after tax)
$163,719,168,377,180,770.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, GSFD beats the other by $163,719,168,377,158,460.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GSFD + PFE for your $10,000?

GSFD: 50%PFE: 50%
100% PFE50/50100% GSFD
Portfolio after 10yr
$103167173821.24M
Annual income
$96,305,393,163,060,640.00/yr
Blended yield
93.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GSFD
No analyst data
Altman Z
0.5
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GSFD buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGSFDPFE
Forward yield2760.91%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$206334347642.44M$49.6K
Annual income after 10y$192,610,786,326,095,000.00$26,258.71
Total dividends collected$205381137054.50M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GSFD vs PFE ($10,000, DRIP)

YearGSFD PortfolioGSFD Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$286,791$276,090.56$9,153$693.39+$277.6KGSFD
2$7,706,881$7,400,015.42$8,593$849.25+$7.70MGSFD
3$194,096,408$185,850,044.68$8,336$1,066.78+$194.09MGSFD
4$4,582,075,357$4,374,392,200.78$8,437$1,384.80+$4582.07MGSFD
5$101,414,232,866$96,511,412,233.78$9,013$1,875.40+$101414.22MGSFD
6$2,104,839,745,904$1,996,326,516,737.79$10,306$2,680.72+$2104839.74MGSFD
7$40,975,082,919,702$38,722,904,391,584.13$12,820$4,101.38+$40975082.91MGSFD
8$748,349,752,637,496$704,506,413,913,414.90$17,673$6,826.70+$748349752.62MGSFD
9$12,825,758,239,574,374$12,025,024,004,252,254.00$27,543$12,591.86+$12825758239.55MGSFD
10$206,334,347,642,439,580$192,610,786,326,095,000.00$49,560$26,258.71+$206334347642.39MGSFD

GSFD vs PFE: Complete Analysis 2026

GSFDStock

Global Seafood Technologies, Inc. engages in the processing and packaging of shrimp for seafood restaurant chains and retail grocery outlets in the United States. The company operates through the Seafood, Fishing Bait, and Freshwater Shrimp segments. The Seafood segment performs processing, packaging, and storage of shrimp and other seafood products. The company provides frozen shrimp in various sizes and descriptions, which are packaged for commercial or consumer use. Frozen, headless shrimp with shell, is the principal product processed and packaged in one-pound and two-pound packages. Peeled shrimp is also processed under private labels for customers or for distribution to restaurants, and it is used in ready-to-cook meal kits for supermarket distribution. The Fishing Bait segment packages and distributes recreational fishing bait products. Its Killer Bee Bait products include varieties of bait shrimp, catfish bait, cut squid, whole squid, cigar minnows, ballyhoo, frozen chum, and menhaden oil. Killer Bee Bait products are sold through retail outlets and at independent marinas and bait shops. The Freshwater Shrimp segment engages in the development and harvesting of farm-grown and freshwater shrimp through its hatchery and nursery facility for sale to independent aquaculture farmers. Global Seafood Technologies is based in Biloxi, Mississippi.

Full GSFD Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GSFD vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GSFD vs SCHDGSFD vs JEPIGSFD vs OGSFD vs KOGSFD vs MAINGSFD vs JNJGSFD vs MRKGSFD vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.